| Vertex to Participate in Upcoming Investor Conferences |
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Investor Relations, and Manisha Pai, Executive Director, Investor Relations, will participate in the Evercore Biotechnology Summit on Wednesday, May 21, 2025. Dr. Reshma Kewalramani, Chief Executive Officer and President, will participate in a fireside chat at the Bernstein 41st Annual Strategic Decisions. |
businesswire.com |
2025-05-15 20:05:00 |
Czytaj oryginał (ang.) |
| Best Biotech Stocks to Buy in 2025 |
The bear market induced by the Federal Reserve's monetary tightening officially ended in 2023, but it seems no one remembered to tell the biotech sector. |
marketbeat.com |
2025-05-13 12:10:10 |
Czytaj oryginał (ang.) |
| 2 Biotech Stocks That Are Screaming Buys in May |
It's very tempting to pile into the stocks with the strongest positive momentum of the moment -- they've proven themselves and could continue along this path. But in many cases, you could set yourself up for a bigger win if you look to quality companies that have seen their stocks stumble in recent times. |
fool.com |
2025-05-13 11:10:00 |
Czytaj oryginał (ang.) |
| This Stock Just Dropped by 12% in 1 Day. History Says This Will Happen Next |
Vertex Pharmaceuticals (VRTX 3.40%), a leading drugmaker, is performing exceedingly well for the year -- or at least it was, until it released its first-quarter update. The results were not to the market's liking, so much so that they led to a significant post-earnings dip for the stock. |
fool.com |
2025-05-13 08:52:00 |
Czytaj oryginał (ang.) |
| Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years |
Regardless of how stocks are performing right now, history tells us that the market tends to generate solid returns over long periods. Investors can do even better than the average market performance by buying shares of companies likely to beat broader equities. |
fool.com |
2025-05-12 11:08:00 |
Czytaj oryginał (ang.) |
| My Favorite Tariff Safe-Haven Stock to Buy on the Dip |
Uncertainty has weighed on stocks over the past several weeks, pushing the three major indexes lower -- the S&P 500 (^GSPC -0.07%) even temporarily slid into a bear market. What's driven this negative momentum is investors' concerns about the potential impact of import tariffs on corporate earnings. |
fool.com |
2025-05-10 08:12:00 |
Czytaj oryginał (ang.) |
| Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft |
The Investment Committee give you their top names to watch for the second half. |
youtube.com |
2025-05-09 17:38:58 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know |
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2025-05-09 14:06:07 |
Czytaj oryginał (ang.) |
| 4 No-Brainer Stocks to Buy Right Now |
Market volatility and near-term uncertainty can be challenging to deal with these days -- or at any time. However, even in the current environment, there are excellent investment opportunities. |
fool.com |
2025-05-09 10:30:00 |
Czytaj oryginał (ang.) |
| VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations |
Sales from VRTX's new drugs, Casgevy, Alyftrek and Journavx, in Q1 fell short of investor expectations. |
zacks.com |
2025-05-07 12:30:35 |
Czytaj oryginał (ang.) |
| Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip |
Vertex Pharmaceuticals' (VRTX -9.39%) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. |
fool.com |
2025-05-07 08:49:00 |
Czytaj oryginał (ang.) |
| Vertex On Track To Significantly Improve Revenue And Earnings By 2030 |
Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex's diversification efforts are most visible in the progress of its pain management portfolio. The FDA approval of Journavx marks the beginning of a new era for the company. VRTX is not going to be the same company by 2030. I expect notable changes in its margin profile as the company diversifies into new markets. |
seekingalpha.com |
2025-05-07 02:12:20 |
Czytaj oryginał (ang.) |
| Why Did Vertex Pharmaceuticals Stock Fall On Tuesday? |
On Monday, Vertex Pharmaceuticals Incorporated VRTX reported lower-than-expected first-quarter 2025 earnings. |
benzinga.com |
2025-05-06 20:28:44 |
Czytaj oryginał (ang.) |
| VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened |
Vertex reports weaker-than-expected first-quarter 2025 results. The company tightens its total revenue guidance for 2025. |
zacks.com |
2025-05-06 17:00:38 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why. |
The company discloses narrower-than-expected access to its new painkiller. |
barrons.com |
2025-05-06 16:31:00 |
Czytaj oryginał (ang.) |
| Top Stock Movers Now: Vertex, DoorDash, Constellation Energy, and More |
U.S. equities were lower at midday as the market watched for any possible deals involving Trump administration tariffs and awaited tomorrow's statement from the Federal Reserve policymakers following their two-day meeting. The Dow Jones Industrial Average, S&P 500, and Nasdaq all fell. |
investopedia.com |
2025-05-06 16:06:09 |
Czytaj oryginał (ang.) |
| 2 Pharma Stocks Staging Big Post-Earnings Moves |
Biopharmaceutical giants Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Neurocrine Biosciences Inc (NASDAQ:NBIX) are fresh out of the earnings confessional, with very different results. |
schaeffersresearch.com |
2025-05-06 14:43:39 |
Czytaj oryginał (ang.) |
| Why Vertex Pharmaceuticals Stock Is Sinking Today |
Shares of Vertex Pharmaceuticals (VRTX -11.69%) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. |
fool.com |
2025-05-06 14:36:08 |
Czytaj oryginał (ang.) |
| Rising Costs Weigh on Vertex Q1 Earnings |
Here's our initial take on Vertex Pharmaceuticals' (VRTX -0.27%) first-quarter financial report. |
fool.com |
2025-05-06 13:11:46 |
Czytaj oryginał (ang.) |
| Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session |
U.S. stock futures were lower this morning, with the Dow futures falling over 200 points on Tuesday. |
benzinga.com |
2025-05-06 12:08:19 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know |
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. |
zacks.com |
2025-02-25 12:01:28 |
Czytaj oryginał (ang.) |
| 3 Magnificent Growth Stocks to Buy Right Now |
In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy increase in value. |
fool.com |
2025-02-22 07:47:00 |
Czytaj oryginał (ang.) |
| 2 No-Brainer Healthcare Stocks to Buy With $500 Right Now |
Looking for a good area in which to invest? Consider the healthcare sector. |
fool.com |
2025-02-21 07:50:00 |
Czytaj oryginał (ang.) |
| GILD or VRTX: Which Is the Better Value Stock Right Now? |
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2025-02-20 14:45:38 |
Czytaj oryginał (ang.) |
| Vertex to Participate in Upcoming March Investor Conferences |
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Stuart Arbuckle, Executive Vice President and Chief Operating Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET. Charles Wagner, Executive Vice Pres. |
businesswire.com |
2025-02-18 18:05:00 |
Czytaj oryginał (ang.) |
| High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models |
Deshawn "DJ" Chow is one of just over 100 sickle cell patients who have undergone treatment with new gene therapies. CVS Health CEO David Joyner said private insurers and employer-sponsored health plans are looking at how to create a new risk pool arrangement to help manage the costs of the therapies. |
cnbc.com |
2025-02-18 11:52:30 |
Czytaj oryginał (ang.) |
| 3 Stocks That Could Trounce the Market in 2025 |
If you're content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not, you'll need to find stocks that hold the potential to pack more punch. |
fool.com |
2025-02-17 06:32:00 |
Czytaj oryginał (ang.) |
| 2 Healthcare Stocks That Tumbled in 2024 |
Vertex Pharmaceuticals (VRTX -0.77%) and AstraZeneca (AZN -1.17%), two of the world's leading drugmakers, missed last year's strong market rally. Both finished 2024 slightly in the red. |
fool.com |
2025-02-15 10:45:00 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It |
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. |
zacks.com |
2025-02-14 12:01:30 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Announces an Investigation on Behalf of Vertex Pharmaceuticals Incorporated (VRTX) Shareholders Who May Have Been Affected by Fraud |
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine. |
accessnewswire.com |
2025-02-14 09:30:00 |
Czytaj oryginał (ang.) |
| The Ultimate Healthcare Stock to Buy With $500 Right Now |
Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare stocks as a group are barely in positive territory. |
fool.com |
2025-02-14 07:47:00 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing |
Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business. |
fool.com |
2025-02-14 06:35:00 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VRTX |
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine. |
accessnewswire.com |
2025-02-13 09:30:00 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VRTX |
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine. |
accessnewswire.com |
2025-02-12 09:30:00 |
Czytaj oryginał (ang.) |
| Calls of the Day: Charles Schwab, Vertex Pharma and Transocean |
The Investment Committee debate the latest Calls of the Day. |
youtube.com |
2025-02-11 16:21:14 |
Czytaj oryginał (ang.) |
| VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales |
Vertex reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Trikafta/Kaftrio drive year-over-year sales. |
zacks.com |
2025-02-11 14:01:08 |
Czytaj oryginał (ang.) |
| VRTX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Vertex Pharmaceuticals Incorporated investment |
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine. |
accessnewswire.com |
2025-02-11 09:25:00 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals Incorporated (VRTX) Q4 2024 Earnings Call Transcript |
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q4 2024 Earnings Conference Call February 10, 2025 4:30 PM ET Company Participants Susie Lisa - Senior Vice President, Investor Relations Reshma Kewalramani - President and Chief Executive Office Stuart Arbuckle - Chief Operating Officer Charlie Wagner - Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs Evan Seigerman - BMO Capital Markets Jessica Fye - JPMorgan Geoff Meacham - Citibank Michael Yee - Jefferies William Pickering - Bernstein Liisa Bayko - Evercore ISI Phil Nadeau - TD Cowen Eliana Merle - UBS Tazeen Ahmad - Bank of America Dave Risinger - Leerink Partners Olivia Brayer - Cantor Fitzgerald Operator Good day, and welcome to the Vertex Pharmaceuticals Fourth Quarter 2024 Earnings Call. All participants will be in a listen-only mode. |
seekingalpha.com |
2025-02-10 22:26:10 |
Czytaj oryginał (ang.) |
| Markets Steady, Positive; Q4 Earnings Keep Rolling |
Indexes mostly shrugged off +25% steel tariffs announced by President Trump; VRTX, LSCC report for Q4. |
zacks.com |
2025-02-10 21:11:08 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals (VRTX) Misses Q4 Earnings Estimates |
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $3.98 per share, missing the Zacks Consensus Estimate of $3.99 per share. This compares to earnings of $4.20 per share a year ago. |
zacks.com |
2025-02-10 20:11:08 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Announces an Investigation on Behalf of Vertex Pharmaceuticals Incorporated (VRTX) Shareholders Who May Have Been Affected by Fraud |
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine. |
accesswire.com |
2025-01-03 09:25:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Vertex Pharmaceuticals Investors of the Ongoing Investigation into Potential Violations of Securities Laws - VRTX |
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine. |
accesswire.com |
2025-01-02 09:30:00 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know |
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. |
zacks.com |
2025-01-01 12:01:15 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors |
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $402.70, marking a +0.84% move from the previous day. |
zacks.com |
2024-12-31 21:20:46 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested |
Vertex Pharmaceuticals' suzetrigine showed lackluster Phase II results, but I still see potential in the non-addictive pain management market given the opioid crisis. Vertex's dominance in the cystic fibrosis (CF) drug market, including recent FDA approval for Alyftrek, ensures strong revenue and market expansion. The company's pipeline diversification, targeting diabetic peripheral neuropathy, IgA nephropathy, type 1 diabetes, and gene editing, promises long-term growth. |
seekingalpha.com |
2024-12-31 11:02:47 |
Czytaj oryginał (ang.) |
| Shareholders that lost money on Vertex Pharmaceuticals Incorporated(VRTX) should contact Levi & Korsinsky about Securities Fraud Investigation - VRTX |
NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine. |
accesswire.com |
2024-12-31 09:30:00 |
Czytaj oryginał (ang.) |
| Is the Options Market Predicting a Spike in Vertex Pharmaceuticals (VRTX) Stock? |
Investors need to pay close attention to Vertex Pharmaceuticals (VRTX) stock based on the movements in the options market lately. |
zacks.com |
2024-12-30 11:30:27 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals Incorporated (VRTX) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates |
NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine. |
accesswire.com |
2024-12-30 09:25:00 |
Czytaj oryginał (ang.) |
| Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip |
Every investor has heard the phrase "buy low, sell high." It's a simple enough piece of advice that's less simple to apply. |
fool.com |
2024-12-28 10:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Shareholders of an Investigation into Vertex Pharmaceuticals Incorporated (VRTX) Regarding Potential Securities Fraud Allegations |
NEW YORK, NY / ACCESSWIRE / December 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine. |
accesswire.com |
2024-12-27 09:30:00 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip |
Vertex Pharmaceuticals (VRTX 0.72%) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to doubt the long-term potential of this stock, this setback is an opportunity to buy the dip for those who are willing to hold onto it for at least a few years. |
fool.com |
2024-12-26 10:30:00 |
Czytaj oryginał (ang.) |
| Shareholder Rights Advocates at Levi & Korsinsky Investigate Vertex Pharmaceuticals Incorporated (VRTX) Regarding Possible Securities Fraud Violations |
NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine. |
accesswire.com |
2024-12-26 09:30:00 |
Czytaj oryginał (ang.) |
| 3 No-Brainer Stocks to Buy on the Latest Sell-Off |
Warren Buffett's mentor Benjamin Graham once said, "In the short run, the market is a voting machine but in the long run, it is a weighing machine." He understood that stocks are largely driven by investor sentiment, which is inherently fickle over the near term. |
fool.com |
2024-12-24 07:25:00 |
Czytaj oryginał (ang.) |
| Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13 |
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on. |
businesswire.com |
2024-12-23 18:05:00 |
Czytaj oryginał (ang.) |
| Pharma has value names, but it's not a top pick for 2025, says BMO's Evan Siegerman |
Evan Siegerman, BMO biotech analyst, joins 'Power Lunch' to discuss the big winners in the pharmaceutical space in 2025. |
youtube.com |
2024-12-23 17:45:24 |
Czytaj oryginał (ang.) |
| Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek |
The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared to the blockbuster drug Trikafta. |
zacks.com |
2024-12-23 16:46:11 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst |
Vertex Pharmaceuticals Inc VRTX last week announced that the Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR) had met its primary endpoint. |
benzinga.com |
2024-12-23 13:13:58 |
Czytaj oryginał (ang.) |
| Lost Money on Vertex Pharmaceuticals Incorporated (VRTX)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky |
NEW YORK, NY / ACCESSWIRE / December 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine. |
accesswire.com |
2024-12-23 09:45:00 |
Czytaj oryginał (ang.) |
| Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025? |
Vertex Pharmaceuticals (VRTX 0.16%) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global leader in cystic fibrosis (CF) treatments, has established a long track record of earnings growth thanks to this business -- and in recent times has made significant progress on broadening into other billion-dollar treatment areas. |
fool.com |
2024-12-22 06:30:00 |
Czytaj oryginał (ang.) |
| 3 Fantastic Stocks That Could Enjoy a Santa Claus Rally |
Santa Claus will soon be on his way delivering presents to kids around the world. But could the jolly gift-giver bring something for investors, too? |
fool.com |
2024-12-21 08:48:00 |
Czytaj oryginał (ang.) |